Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Journal article
Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58
Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Journal article
Dulal P. et al, (2021), Scientific reports, 11
Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Journal article
Dulal P. et al, (2021), Scientific reports, 11
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Journal article
Voysey M. et al, (2021), The Lancet, 397, 881 - 891
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Journal article
Voysey M. et al, (2021), The Lancet, 397, 99 - 111
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Journal article
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478
Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components
Journal article
Fedosyuk S. et al, (2019), Vaccine, 37, 6951 - 6961
Health and Well-being in Urban Environments
Chapter
Mizdrak A. and Ritchie AJ., (2017), Building Sustainable Cities of the Future, 99 - 115
Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection
Journal article
Ritchie AJ. et al, (2014), Retrovirology, 11
Normal prion protein is expressed on exosomes isolated from human plasma
Journal article
Ritchie AJ. et al, (2013), British Journal of Haematology, 163, 678 - 680
Normal prion protein is expressed on exosomes isolated from human plasma
Journal article
Ritchie AJ. et al, (2013), British Journal of Haematology, 163, 678 - 680
Quantitative and Qualitative Differences in the T Cell Response to HIV in Uninfected Ugandans Exposed or Unexposed to HIV-Infected Partners
Journal article
Pala P. et al, (2013), Journal of Virology, 87, 9053 - 9063
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape
Journal article
Liu MKP. et al, (2012), Journal of Clinical Investigation
Comparison of Sexual Behavior and HIV Risk between Two HIV-1 Serodiscordant Couple Cohorts: The CHAVI 002 Study
Journal article
Ritchie AJ. et al, (2012), PLoS ONE, 7, e37727 - e37727